E-cadherin contributes to the bystander effect of TK/GCV suicide therapy and enhances its antitumoral activity in pancreatic cancer models

Gene Therapy

Volumn 18, Issue 1, 2011, Pages 73-81

  Garcia Rodriguez L ^a,b   Abate Daga, D ^a,b   Rojas, A ^a   Gonzalez J R ^c,d,e   Fillat, C ^a,b  

^a UNIVERSITAT POMPEU FABRA   (Spain)

^b CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED DE ENFERMEDADES RARAS CIBERER   (Spain)

^c CENTRE FOR RESEARCH IN ENVIRONMENTAL EPIDEMIOLOGY CREAL   (Spain)

^d HOSPITAL DEL MAR   (Spain)

^e Centro de Investigación Biomé Dica en Red de Epidemiologia y Salud Pú Blica   (Spain)

Author keywords

bystander effect; E cadherin; suicide gene therapy

Indexed keywords

ADENOVIRUS VECTOR; GANCICLOVIR; GAP JUNCTION PROTEIN; PROTEIN BCL 2; SITIMAGENE CERADENOVEC; UVOMORULIN;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BYSTANDER EFFECT; CANCER GENE THERAPY; CANCER MODEL; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOTOXICITY; GAP JUNCTION; GENE SILENCING; HUMAN; HUMAN CELL; IN VIVO STUDY; PANCREAS ADENOCARCINOMA; PANCREAS CANCER; PANCREAS DUCT; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR CELL; XENOGRAFT;

ANTINEOPLASTIC AGENTS; BYSTANDER EFFECT; CADHERINS; GANCICLOVIR; GENE THERAPY; GENES, TRANSGENIC, SUICIDE; GENETIC VECTORS; PANCREATIC NEOPLASMS; RETROVIRIDAE; SIMPLEXVIRUS; THYMIDINE KINASE; TRANSFECTION; TUMOR CELLS, CULTURED;

SIMPLEXVIRUS;

EID: 78650992294     PISSN: 09697128     EISSN: 14765462     Source Type: Journal    
DOI: 10.1038/gt.2010.114     Document Type: Article

References (44)

1. Immonen A, Vapalahti M, Tyynela K, Hurskainen H, Sandmair A, Vanninen R, et al. AdvHSV-tk gene therapy with intravenous ganciclovir improves survival in human malignant glioma: a randomised, controlled study. Mol Ther 2004; 10: 967-972.
2. Nasu Y, Saika T, Ebara S, Kusaka N, Kaku H, Abarzua F, et al. Suicide gene therapy with adenoviral delivery of HSV-tK gene for patients with local recurrence of prostate cancer after hormonal therapy. Mol Ther 2007; 15: 834-840.
3. Tomicic MT, Thust R, Kaina B. Ganciclovir-induced apoptosis in HSV-1 thymidine kinase expressing cells: critical role of DNA breaks, Bcl-2 decline and caspase-9 activation. Oncogene 2002; 21: 2141-2153.
4. Fillat C, Carrio M, Cascante A, Sangro B. Suicide gene therapy mediated by the herpes simplex virus thymidine kinase gene/ganciclovir system: fifteen years of application. Curr Gene Ther 2003; 3: 13-26.
5. Culver KW, Ram Z, Wallbridge S, Ishii H, Oldfield EH, Blaese RM. In vivo gene transfer with retroviral vector-producer cells for treatment of experimental brain tumors [see comments]. Science 1992; 256: 1550-1552.
6. Caruso M, Panis Y, Gagandeep S, Houssin D, Salzmann JL, Klatzmann D. Regression of established macroscopic liver metastases after in situ transduction of a suicide gene. Proc Natl Acad Sci USA 1993; 90: 7024-7028.
7. Mesnil M, Piccoli C, Tiraby G, Willecke K, Yamasaki H. Bystander killing of cancer cells by herpes simplex virus thymidine kinase gene is mediated by connexins. Proc Natl Acad Sci USA 1996; 93: 1831-1835.
8. Vrionis FD, Wu JK, Qi P, Waltzman M, Cherington V, Spray DC. The bystander effect exerted by tumor cells expressing the herpes simplex virus thymidine kinase (HSVtk) gene is dependent on connexin expression and cell communication via gap junctions. Gene Therapy 1997; 4: 577-585.
9. Carrio M, Mazo A, Lopez-Iglesias C, Estivill X, Fillat C. Retrovirus-mediated transfer of the herpes simplex virus thymidine kinase and connexin26 genes in pancreatic cells results in variable efficiency on the bystander killing: implications for gene therapy. Int J Cancer 2001; 94: 81-88.
10. Jimenez T, Fox WP, Naus CC, Galipeau J, Belliveau DJ. Connexin over-expression differentially suppresses glioma growth and contributes to the bystander effect following HSV-thymidine kinase gene therapy. Cell Commun Adhes 2006; 13: 79-92.
11. 2+ in mouse epidermal cells is controlled by E-cadherin. J Cell Biol 1991; 114: 545-555.
12. Fujimoto K, Nagafuchi A, Tsukita S, Kuraoka A, Ohokuma A, Shibata Y. Dynamics of connexins, E-cadherin and alpha-catenin on cell membranes during gap junction formation. J Cell Sci 1997; 110: 311-322.
13. Hernandez-Blazquez FJ, Joazeiro PP, Omori Y, Yamasaki H. Control of intracellular movement of connexins by E-cadherin in murine skin papilloma cells. Exp Cell Res 2001; 270: 235-247.
14. Nishimura M, Saito T, Yamasaki H, Kudo R. Suppression of gap junctional intercellular communication via 5¢ CpG island methylation in promoter region of E-cadherin gene in endometrial cancer cells. Carcinogenesis 2003; 24: 1615-1623.
15. Shaw RM, Fay AJ, Puthenveedu MA, Von Zastrow M, Jan YN, Jan LY. Microtubule plus-end-tracking proteins target gap junctions directly from the cell interior to adherens junctions. Cell 2007; 128: 547-560.
16. Cascante A, Huch M, Rodriguez LG, Gonzalez JR, Costantini L, Fillat C. Tat8-TK/GCV suicide gene therapy induces pancreatic tumor regression in vivo. Hum Gene Ther 2005; 16: 1377-1388.
17. Sasaki CY, Lin H, Passaniti A. Expression of E-cadherin reduces bcl-2 expression and increases sensitivity to etoposide-induced apoptosis. Int J Cancer 2000; 86: 660-666.
18. Witta SE, Gemmill RM, Hirsch FR, Coldren CD, Hedman K, Ravdel L, et al. Restoring E-cadherin expression increases sensitivity to epidermal growth factor receptor inhibitors in lung cancer cell lines. Cancer Res 2006; 66: 944-950.
19. Black PC, Brown GA, Inamoto T, Shrader M, Arora A, Siefker-Radtke AO, et al. Sensitivity to epidermal growth factor receptor inhibitor requires E-cadherin expression in urothelial carcinoma cells. Clin Cancer Res 2008; 14: 1478-1486.
20. Ferreira P, Oliveira MJ, Beraldi E, Mateus AR, Nakajima T, Gleave M, et al. Loss of functional E-cadherin renders cells more resistant to the apoptotic agent taxol in vitro. Exp Cell Res 2005; 310: 99-104.
21. Fujimoto K, Nagafuchi A, Tsukita S, Kuraoka A, Ohokuma A, Shibata Y. Dynamics of connexins, E-cadherin and alpha-catenin on cell membranes during gap junction formation. J Cell Sci 1997; 110 (Part 3): 311-322.
22. Laird DW. The life cycle of a connexin: gap junction formation, removal, and degradation. J Bioenerg Biomembr 1996; 28: 311-318.
23. Wei CJ, Francis R, Xu X, Lo CW. Connexin43 associated with an N-cadherin-containing multiprotein complex is required for gap junction formation in NIH3T3 cells. J Biol Chem 2005; 280: 19925-19936.
24. Qin H, Shao Q, Igdoura SA, Alaoui-Jamali MA, Laird DW. Lysosomal and proteasomal degradation play distinct roles in the life cycle of Cx43 in gap junctional intercellular communication-deficient and -competent breast tumor cells. J Biol Chem 2003; 278: 30005-30014.
25. Trepel M, Stoneham CA, Eleftherohorinou H, Mazarakis ND, Pasqualini R, Arap W, et al. A heterotypic bystander effect for tumor cell killing after adeno-associated virus/phage-mediated, vascular-targeted suicide gene transfer. Mol Cancer Ther 2009; 8: 2383-2391.
26. House MG, Guo M, Iacobuzio-Donahue C, Herman JG. Molecular progression of promoter methylation in intraductal papillary mucinous neoplasms (IPMN) of the pancreas. Carcinogenesis 2003; 24: 193-198.
27. Dansranjavin T, Mobius C, Tannapfel A, Bartels M, Wittekind C, Hauss J, et al. E-cadherin and DAP kinase in pancreatic adenocarcinoma and corresponding lymph node metastases. Oncol Rep 2006; 15: 1125-1131.
28. Winter JM, Ting AH, Vilardell F, Gallmeier E, Baylin SB, Hruban RH, et al. Absence of E-cadherin expression distinguishes noncohesive from cohesive pancreatic cancer. Clin Cancer Res 2008; 14: 412-418.
29. Von Burstin J, Eser S, Paul MC, Seidler B, Brandl M, Messer M, et al. E-cadherin regulates metastasis of pancreatic cancer in vivo and is suppressed by a SNAIL/HDAC1/ HDAC2 repressor complex. Gastroenterology 2009; 137: 361-371, 371 e361-e365.
30. Cavallaro U, Christofori G. Cell adhesion and signalling by cadherins and Ig-CAMs in cancer. Nat Rev Cancer 2004; 4: 118-132.
31. Arumugam T, Ramachandran V, Fournier KF, Wang H, Marquis L, Abbruzzese JL, et al. Epithelial to mesenchymal transition contributes to drug resistance in pancreatic cancer. Cancer Res 2009; 69: 5820-5828.
32. Nikolova DA, Asangani IA, Nelson LD, Hughes DP, Siwak DR, Mills GB, et al. Cetuximab attenuates metastasis and u-PAR expression in non-small cell lung cancer: u-PAR and E-cadherin are novel biomarkers of cetuximab sensitivity. Cancer Res 2009; 69: 2461-2470.
33. Villanueva A, Garcia C, Paules AB, Vicente M, Megias M, Reyes G, et al. Disruption of the antiproliferative TGF-beta signaling pathways in human pancreatic cancer cells. Oncogene 1998; 17: 1969-1978.
34. Cascante A, Abate-Daga D, Garcia-Rodriguez L, Gonzalez JR, Alemany R, Fillat C. GCV modulates the antitumoural efficacy of a replicative adenovirus expressing the Tat8-TK as a late gene in a pancreatic tumour model. Gene Therapy 2007; 14: 1471-1480.
35. He TC, Zhou S, da Costa LT, Yu J, Kinzler KW, Vogelstein B. A simplified system for generating recombinant adenoviruses. Proc Natl Acad Sci USA 1998; 95: 2509-2514.
36. Becker TC, Noel RJ, Coats WS, Gomez-Foix AM, Alam T, Gerard RD, et al. Use of recombinant adenovirus for metabolic engineering of mammalian cells. Methods Cell Biol 1994; 43 (Part A): 161-189.
37. Bewig B, Schmidt WE. Accelerated titering of adenoviruses. Biotechniques 2000; 28: 870-873.
38. Yang ZG, Chen Z, Ni Q, Xu N, Shao JB, Yao HP. Inhibition of hepatitis B virus surface antigen expression by small hairpin RNA in vitro. World J Gastroenterol 2005; 11: 498-502.
39. Ortiz-Abalia J, Sahun I, Altafaj X, Andreu N, Estivill X, Dierssen M, et al. Targeting Dyrk1A with AAVshRNA attenuates motor alterations in TgDyrk1A, a mouse model of Down syndrome. Am J Hum Genet 2008; 83: 479-488.
40. Zuco V, Zanchi C, Cassinelli G, Lanzi C, Supino R, Pisano C, et al. Induction of apoptosis and stress response in ovarian carcinoma cell lines treated with ST1926, an atypical retinoid. Cell Death Differ 2004; 11: 280-289.
41. Kapoor P, Saunders MM, Li Z, Zhou Z, Sheaffer N, Kunze EL, et al. Breast cancer metastatic potential: correlation with increased heterotypic gap junctional intercellular communication between breast cancer cells and osteoblastic cells. Int J Cancer 2004; 111: 693-697.
42. Carrio M, Romagosa A, Mercade E, Mazo A, Nadal M, Gomez-Foix AM, et al. Enhanced pancreatic tumor regression by a combination of adenovirus and retrovirus-mediated delivery of the herpes simplex virus thymidine kinase gene. Gene Therapy 1999; 6: 547-553.
43. Heitjan DF, Manni A, Santen RJ. Statistical analysis of in vivo tumor growth experiments. Cancer Res 1993; 53: 6042-6050.
44. Pinheiro JC, Bates DM. Mixed-Effects Models in S and S-PLUS. Springer-Verlag: New York, 2000.